Press Room - Sanofi US News

Menu

Media Room Menu

Month Year

Month Year

Mar 28, 2017

Sanofi and Regeneron Announce FDA Approval of Dupixent® (dupilumab), the First Targeted Biologic Therapy for Adults with Moderate-to-Severe Atopic Dermatitis

- Dupixent will be available later this week to U.S. patients suffering from this chronic and debilitating form of eczema -
Mar 22, 2017

Sanofi Genzyme Extends its Multiple Myeloma Journey Partners Program to Cities Nationwide to Help Improve Patient Outcomes through Peer-to-Peer Education

- During Multiple Myeloma Month Sanofi Genzyme is Reinforcing its Commitment to Help Patients Live with the Second Most Common Blood Cancer in the World -
Mar 21, 2017

Sanofi Announces Results of First-of-Its-Kind Social Experiment Revealing Real-Life Impact of Symptoms on Allergy Sufferers in the U.S.

The makers of Xyzal® Allergy 24HR, now available over-the-counter (OTC) at full prescription strength, are teaming up with Dr. Neeta Ogden to Encourage Allergy Sufferers to 'Wise Up, Rise Up'
- Video 1
- Photos 3
Mar 7, 2017

Sanofi Pasteur and MedImmune Collaborate on Investigational Monoclonal Antibody for Illnesses Associated with RSV

Respiratory Syncytial Virus is the most common cause of lung inflammation and pneumonia in infants
Mar 7, 2017

Sanofi and Regeneron to Present New Phase 3 Praluent® (alirocumab) Injection Clinical Trial Analyses at ACC.17 Scientific Sessions

Show per page

Print
Email page
RSS

You are about to leave www.sanofi.us

If you wish to continue to this external website, click Proceed. It is provided for information only. Sanofi assumes no responsibility for the information presented on this website.